A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants

The Egyptian Journal of Bronchology

Table 5 Neutralization efficacy of EUA approved mAbs against SARS-CoV-2 variants of concern

Monoclonal antibody	Mechanism of action	Alpha-variant	Beta-variant	Gamma-variant	Delta variant
Bamlanivimab (LY-CoV555)	Binds to overlapping sites at RBD and blocks attachment to ACE2 receptors	Retains activity [55, 88, 90]	Complete loss of activity [55, 84, 88, 90]	Complete loss of activity [91]	Complete loss of activity [84]
Etesevimab (LYCoV016/CB6)		Retains activity [55, 88]	High reduction in activity (in combination with LY-CoV555) [55, 88]	High reduction in activity [55, 84, 88, 91]	Retains activity [84]
Casirivimab (REGN10933)		Retains activity [55, 84, 88]	High reduction in activity [55, 84, 88, 91]	High reduction in activity [55, 84, 88, 90]
Casirivimab (REGN10933)	Binds to RBD and blocks attachment of the virus				Retains activity [84]
Imdevimab (REGN10987)	Binds to RBD and blocks attachment of the virus	Retains activity [55, 84, 88, 91]	Retains activity [55, 84, 88, 91]	Retains activity [55, 84, 88, 91]	Retains activity/High reduction inactivity [84, 91]
Sotorivimab (VIR-7831, GSK4182136)	Prevents membrane fusion after viral binding	Retains activity [92]	Retains activity [92]	Retains activity [92]	No data available [88]
Tocillizumab	Inhibits binding of IL6 with its receptor IL-6R	No data available	No data available	No data available	No data available